This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
For the next year, Amgen and Boston Children’s Hospital will use genetic analysis to study pain sensitivity. The biotech giant based in Thousand Oaks will work with patients who have abnormal pain conditions, and the hospital will validate genetic markers as potential targets for new therapies, the two announced in a press release on Oct. 16. “Traditional Read More →